USPTO issued patent grant US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. on March 31, 2026, covering long-acting GLP-1/GIP dual agonist compounds for Type II diabetes treatment. The patent (2 claims) protects compounds with dual agonistic activity on GLP-1 and GIP receptors, with CPC classifications A61K 47/64, A61P 3/04, A61P 3/10, and C07K 14/605. The original application (No. 18602255) was filed March 12, 2024.

Pharmaceutical companies developing similar dual-agonist diabetes therapies should conduct freedom-to-operate analyses before proceeding with clinical development or commercialization to assess potential patent infringement exposure. Competitors may need to explore licensing arrangements with the patent holder or design around the claimed compounds.